PeptiDream Inc. Overview
Pro stress-test →PeptiDream engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. The company is largely credited with establishing the macrocyclic peptide field with high global reputation across the pharma industry.
Strategic Profile
Pro stress-test →The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates. Revenue generation is predominantly through strategic collaborations with leading global pharmaceutical companies, licensing access to its PDPS technology and collaborating on drug discovery projects, securing upfront payments, research funding, milestone payments, and potential royalties.
Competitive Landscape
Pro stress-test →PeptiDream is positioned as the global leader in peptide therapeutics discovery, established in 2006 and credited with establishing the macrocyclic peptide field. The company faces competition from emerging biotech firms, but maintains strategic advantages through its proprietary PDPS platform, extensive pharma partnerships, and integrated radiopharmaceutical subsidiary (PDRadiopharma).
Industry Context
PeptiDream Inc. operates in Biopharmaceutical - Drug Discovery and Development (Peptide Therapeutics).
Key facts
Founded: 2006 · Headquarters: Kawasaki, Japan · Employees: 750+ · Revenue: $323.0M (2024) · Market cap: $1.4B USD (244.8B JPY as of March 2026)